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Abstract
Background: Multiple health conditions are increasingly a problem for adults with musculoskeletal conditions.
However, multimorbidity research has focused primarily on the elderly and those with a limited subset of
musculoskeletal disorders. We sought to determine whether associations between multimorbidity and additional
burden differ with specific forms of musculoskeletal conditions among working-age adults.
Methods: Data were sourced from a nationally representative Australian survey. Specific musculoskeletal conditions
examined were osteoarthritis; inflammatory arthritis; other forms of arthritis or arthropathies; musculoskeletal
conditions not elsewhere specified; gout; back pain; soft tissue disorders; or osteoporosis. Multimorbidity was
defined as the additional presence of one or more of the Australian National Health Priority Area conditions. Burden
was assessed by self-reported measures of: (i) self-rated health (ii) musculoskeletal-related healthcare and medicines
utilisation and, (iii) general healthcare utilisation. Associations between multimorbidity and additional health or
healthcare utilisation burden among working-age adults (aged 18 – 64 years of age) with specific musculoskeletal
conditions were estimated using logistic regression, adjusting for confounders. Interaction terms were fitted to
identify whether there were specific musculoskeletal conditions where multimorbidity was more strongly associated
with poorer health or greater healthcare utilisation than in the remaining musculoskeletal group.
Results: Among working-age adults, for each of the specified musculoskeletal conditions, multimorbidity was
associated with similar, increased likelihood of additional self-rated health burden and certain types of healthcare
utilisation. While there were differences in the relationships between multimorbidity and burden for each of the
specific musculoskeletal conditions, no one specific musculoskeletal condition appeared to be consistently
associated with greater additional health burden in the presence of multimorbidity across the majority of self-rated
health burden and healthcare use measures.
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Conclusions: For working-age people with any musculoskeletal conditions examined here, multimorbidity increases
self-reported health and healthcare utilisation burden. As no one musculoskeletal condition appears consistently
worse off in the presence of multimorbidity, there is a need to better understand and identify strategies that
acknowledge and address the additional burden of concomitant conditions for working-age adults with a range of
musculoskeletal conditions.
Keywords: Multimorbidity, Musculoskeletal conditions, Quality of life, Healthcare utilisation
Background
Musculoskeletal conditions are a grouping of clinically
distinct but characteristically painful conditions af-
fecting joints, bones and muscles. Collectively, mus-
culoskeletal conditions have one of the highest
population prevalence of any chronic conditions [1].
Although musculoskeletal conditions are relatively
heterogeneous and differ in aetiology and prognosis,
these conditions are generally progressive or fluctuat-
ing in nature, and often involve complex treatments
or procedures [2]. As a result, musculoskeletal condi-
tions place a heavy health burden on individuals,
health systems and society [1, 3–11]. Globally muscu-
loskeletal conditions are the second most common
cause of healthy years lost to morbidity [4, 5] with
adverse impacts on quality of life [12].
Musculoskeletal conditions affect all age groups, but
are more common with increasing age. Nonetheless,
nearly one in five working-age adults are diagnosed with
a musculoskeletal condition [13–15]. For working-age
adults, musculoskeletal conditions pose additional em-
ployment, reproductive health, social and financial
challenges [3, 16–19].
People with musculoskeletal conditions are often living
with additional chronic conditions alongside [13, 14, 17,
20–30]. Chronic co-occurring conditions are termed
multimorbidity [20, 23], or in the context of a primary
condition, comorbidity [14, 20, 31]. Like with musculo-
skeletal conditions, multimorbidity also increases health
expenditure [32], usage of healthcare services, polyphar-
macy, premature mortality, and negatively impacts
physical functioning and quality of life [28, 33–37].
These factors suggest the need for clinical and policy
efforts to adapt to challenges faced by working-age
people with musculoskeletal conditions by considering
the possible impacts of other conditions [2, 22, 24, 26–
28, 32]. With ageing populations in many developed
countries, delayed retirement has been advocated as a
possible strategy for sustaining economic growth [38].
Both longevity and delayed retirement could have implica-
tions on workforce participation for the increasing num-
bers of adults experiencing magnified physical disability
and reduced quality of life from accumulating conditions
alongside musculoskeletal conditions [30, 38, 39].
We previously examined the prevalence of and associ-
ations between multimorbidity and self-rated health or
healthcare burden measures among working-age adults
with any musculoskeletal condition when using three
different ways of defining multimorbidity [40, 41].
Regardless of the definition used, multimorbidity was
highly associated with the majority of the health burden
measures within the combined musculoskeletal popula-
tion [41]. These findings highlight the level of additional
self-rated health and healthcare utilisation burden asso-
ciated with multimorbidity within the broad working-
age population with any musculoskeletal condition.
There are a number of gaps in the existing evidence
base for the relationships between multimorbidity and
additional burden in those with musculoskeletal condi-
tions. Both multimorbidity and musculoskeletal condi-
tion research usually examines older populations (i.e.,
aged 65 years and over), and these populations are
predominately sampled within clinical settings, rather
than being population representative. Additionally, when
multimorbidity research includes musculoskeletal condi-
tions it sometimes focuses exclusively on a singular
musculoskeletal condition (e.g. osteoarthritis [42]) or a
limited subset (e.g. arthritis conditions [29], and rheum-
atic conditions [30]), rather than including the breadth
of musculoskeletal conditions. Particularly overlooked
musculoskeletal conditions in the context of multimor-
bidity research include chronic back pain, gout, and
osteoporosis. Furthermore, when determining the
self-rated health burden of multimorbidity, research
tends to combine musculoskeletal conditions into
broad umbrella categories [13–15, 21, 23, 43], and it
is unclear if there are some people with specific
forms of musculoskeletal conditions who are more
impacted by multimorbidity than others. For these
reasons, there is a lack of understanding of whether
health burden associated with multimorbidity varies
for specific musculoskeletal conditions.
Therefore, we sought to determine whether working-
age adults with specific forms of musculoskeletal condi-
tions are worse off in the presence of multimorbidity
compared to the rest of the musculoskeletal sample.
Identifying the musculoskeletal sub-population(s) most
affected by the additional burden of multimorbidity
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could aid priority setting, and could help determine
the musculoskeletal populations in which to develop,
evaluate and apply targeted interventions.
Methods
Australia’s National Health Survey 2007–2008 (NHS 07-08)
data used in this analysis were provided by the Australian
Bureau of Statistics through their Microdata program [44].
The NHS 07-08 survey is completed by an adult and, where
applicable, child, from each household sampled. House-
holds are sampled by the Australian Bureau of Statistics
from all Australian States and Territories and across all age
groups, ensuring it is nationally representative. The ques-
tions asked, response rate, survey design and sampling
strategy are reported elsewhere [44]. None of the authors
were involved in the development of the questionnaire or
data collection. Permission was obtained from the ABS to
conduct this secondary cross-sectional analysis. La Trobe
University Human Ethics Committee granted an exemption
for this study as there was negligible risk involved in an
analysis of previously collected, de-identified data.
For this study, the sample is NHS 07-08 respondents
aged between 18 and 64 years with chronic musculos-
keletal conditions. ‘Musculoskeletal conditions’, as cate-
gorised by the Australian Bureau of Statistics, included:
osteoarthritis; inflammatory arthritis; other forms of
arthritis or arthropathies; musculoskeletal conditions not
elsewhere specified; gout; back pain; soft tissue disorders;
and osteoporosis. The exposure is multimorbidity opera-
tionalised as presence of one or more of the following
Australian National Health Priority Area condition cat-
egories (in addition to a musculoskeletal condition): dia-
betes; cancer; cardiovascular disease; asthma; chronic
obstructive pulmonary disease; and mental health disor-
ders [45]. Both the musculoskeletal conditions and the
condition categories included in the multimorbidity vari-
able were “chronic”, i.e. current and present for at least
6 months. Conditions were identified through self-
reports of doctor diagnoses in response to open ended
questions in combination with a series of prompts for
some specific conditions, designed to provide respon-
dents with the opportunity to report detailed infor-
mation on all chronic conditions they experience. All
chronic conditions reported were then coded by the
Australian Bureau of Statistics to a categorisation system
based on the Tenth Revision of the International Clas-
sification of Diseases and Health Related Problems
(ICD-10-AM). Further details on the specific diagnoses
included in each condition category that contributed to
multimorbidity are published elsewhere [40, 41].
For each specific musculoskeletal condition, we exam-
ined the associations between the exposure (multimorbid-
ity) and a range of burden measures. See Table 1 for the
description of these burden measures.
Analyses
To determine whether working-age adults with some
specific forms of musculoskeletal conditions are worse
off in the presence of multimorbidity, compared to the
rest of the musculoskeletal sample, we conducted three
types of analyses.
1) Prevalence of conditions comprising multimorbidity
in working-age Australians with specific
musculoskeletal conditions was estimated.
To account for the survey design, the replicant
weights generated by the Australian Bureau of
Statistics were applied using the jack-knife
method [46], allowing the prevalence estimates
to be representative of the Australian population.
2) Associations between multimorbidity and additional
health or healthcare utilisation burden among
working-age adults with specific musculoskeletal
conditions were estimated. Although we considered
an ordinal logistic regression model for the variables
“fair to poor health status” and “pain limiting work”,
because the proportional odds assumption did not
hold, it was not possible to treat these variables as
ordered categories. It was also not possible to analyse
the Kessler Psychological Distress Scale score as a
continuous outcome as the data were not normally
distributed, and it was not possible to transform the
data to approximate normality. Therefore, the
associations between multimorbidity and each burden
measure among people with the specific nominated
musculoskeletal condition were estimated using
logistic regression. In each case, the dependent
variable was the burden measure (see Table 1), and
multimorbidity was the independent variable. These
associations were estimated in the total working-age
sample with musculoskeletal conditions, and then
stratified by each specific musculoskeletal condition
grouping (regardless of the presence of other
musculoskeletal conditions).
3) Interaction terms were fitted to identify if the
associations between multimorbidity and the various
burden measures differed between the specific
musculoskeletal conditions. To do this, the analysis
was restricted to the working-age sample with any
form of musculoskeletal condition, and the interaction
term was fitted between multimorbidity and the
presence of the specific musculoskeletal condition
grouping. Significant (p < 0.05) interaction terms
would indicate a greater (or lesser) burden of multi-
morbidity for a specific musculoskeletal condition
compared to the rest of the musculoskeletal sample.
Logistic regression and interaction analyses were ad-
justed for age, gender, household income quintiles as a
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marker of socioeconomic status (SES), education, smok-
ing status (current, past, never), and moderate to high
risky alcohol consumption as potential confounders. All
statistical analyses were performed using Stata (release
10.1, College Station, TX).
Results
Of the 20,788 people interviewed from the 15,792
households sampled (a response rate of 91%), 12,604
people were working-aged (18 to 64 years). Of the
working-age adults, 50.1% were female and 37.0% were
aged between 18 and 34 years, 34.6% were aged between
35 and 59 years, and 28.3% were 60 to 64 years old.
Chronic musculoskeletal conditions were reported by
36.1% of the working-age adults. Back pain was the most
common (19.8%), followed by osteoarthritis (7.9%); other
arthritis or arthropathies (8.1%); gout (4.7%); soft tissue
disorders (3.2%); inflammatory arthritis (2.5%); osteo-
porosis (2.3%) or other musculoskeletal conditions not
elsewhere specified (0.9%). The prevalence of multimor-
bidity among working-age adults was 15.3% (Table 2).
Among the working-age adults, the prevalence of the
chronic conditions included in the multimorbidity defin-
ition were as follows: mental health disorders 13.4%;
asthma 9.7%; cardiovascular diseases (CVD) 5.2%; dia-
betes 3.4%; chronic obstructive pulmonary dis-
ease (COPD) 2.1%; and cancer 1.4% (Table 2).
Depending on the specific musculoskeletal condition
grouping, the prevalence of multimorbidity varied from
37.8% (among those with gout) to 53.1% (among those
Table 1 Description of burden measures
Burden Measure Description Timeframe
Self-rated health
Fair to poor health status A response of either “fair” or “poor” [59] to the question
“In general would you say that [your/(proxy name)] health
is excellent, very good, good, fair or poor” [59].
In the four weeks prior to
interview
High distress A Kessler Psychological Distress Scale-10 (K10) score
indicating high (>22 points) to very high severity
of distress (30-50 points) [60].
In the four weeks prior to
interview
Pain interference with activities A response of “moderately” to “extremely” to the extent
bodily pain interfered with normal work. Response options:
not at all; a little bit; moderately; quite a bit; extremely and
did not experience bodily pain.
In the four weeks prior to
interview
Moderate to severe pain rating A response of “moderate”, “severe” or “very severe” to
the extent of bodily pain felt. Response options: none;
very mild; mild; moderate; severe; or very severe.
In the four weeks prior to
interview
Musculoskeletal-relateda healthcare and medicines utilisation
Visit general practitioner (GP) for
arthritis or osteoporosis
Self-reports of arthritis or osteoporosis-related
GP consultations.
In the two weeks prior to the
interview
Visit arthritis or osteoporosis
specialist(s)
Self-reports of arthritis or osteoporosis-related
specialist consultations.
In the two weeks prior to the
interview
Pain medicines use Self-reports of pain medicines use including analgesics. In the two weeks prior to the
interview
Musculoskeletal (MSK) medicines use Self-reports of up to three MSK-related, main pharmaceutical
medicines used. This included vitamins and mineral
supplements such as vitamin D, calcium, glucosamine
and various marine-based products, natural or
herbal treatments.
In the two weeks prior to the
interview
General healthcare utilisation
Visit other specialist(s) Self-reports of consulting a specialist for condition other than arthritis or
osteoporosis.
In the 12 months prior to the
interview
Visit physiotherapist(s) Self-reports of consulting a physiotherapist. In the 12 months prior to the
interview
Did not visit health professional (HP). Self-reports of not consulting a health professional. In the 12 months prior to the
interview
Visit chemist(s) for advice only Self-reports of consulting a chemist for advice only
(i.e., not to fill scripts).
In the 12 months prior to the
interview
Visit chiropractor(s) Self-reports of consulting a chiropractor. In the 12 months prior to the
interview
aAll musculoskeletal-related healthcare, pain and medicines use data were collected only for NHS respondents with current arthritis or osteoporosis (osteoporosis,
osteopenia or gout, rheumatism or arthritis, osteoarthritis, rheumatoid arthritis, or other type (specified))
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with inflammatory arthritis) (Table 2). The three most
common comorbidities alongside any musculoskeletal
condition were typically a mental health disorder, followed
by asthma or CVD. There were minimal differences in the
frequency pattern of co-occurring conditions for
working-age adults with specific musculoskeletal condi-
tions (Table 2), excepting for those with gout, where dia-
betes was more common than asthma. Furthermore,
although cancer was typically the least common co-
occurring condition alongside the specific musculoskeletal
conditions, for those with gout, COPD was least common,
and for those with for those with “other musculoskeletal
conditions” diabetes was the least common co-morbidity.
Among working-age adults with specific musculoskeletal
conditions, 35.7 to 69.1% also reported the presence of an
additional musculoskeletal condition (Table 3) (lowest
among those with back pain and highest among those
with osteoporosis).
Musculoskeletal condition, multimorbidity and self-rated
health burden
Among working-age adults, multimorbidity was con-
sistently associated with greater additional self-rated
health burden, with minimal differences across these
specific musculoskeletal conditions (Table 4). There
were insufficient numbers in the “other musculoskel-
etal” condition group to calculate valid estimates; there-
fore results are not presented in Tables 4, 5 and 6.
Across the specific musculoskeletal conditions, while
there were some differences in association between
multimorbidity and self-rated health burden measures,
these differences were mostly inconsistent and estimates
were imprecise, due to small sample sizes for some
specific musculoskeletal conditions.
However, interaction analyses between each specific
musculoskeletal condition and multimorbidity for each
of the self-rated health burden measures identified two
instances of significant between group differences.
Firstly, the relationship between multimorbidity and the
measure “high distress” was significantly greater in those
with back pain compared to the remainder of the mus-
culoskeletal group (Table 4). Specifically, of working-age
adults with chronic back pain (n = 2493), a lower
proportion (8.0% n = 117/1467) without multimorbidity
reported high distress compared to 38.8% (n = 398/1025)
who had multimorbidity (OR = 8.0, 95%CI: 6.0, 10.8). In
those with another form of musculoskeletal condition
(other than back pain, n = 2061) those with multimor-
bidity also reported greater rates of high distress (30.7%,
247/806) compared to those without multimorbidity
(8.2%, n = 103/1255, OR = 4.1, 95%CI: 3.0, 5.5). There-
fore, although multimorbidity is a risk factor for high
distress in all forms of musculoskeletal condition, it is a
stronger risk factor in those with back pain (interaction
p-value = 0.001). Secondly, the observed association for
multimorbidity on pain interfering with work was
significantly greater for those with soft-tissue disorders
than the rest of the musculoskeletal group. Specifically,
of working-age adults with soft-tissue disorders (n = 404),
37.2% (74/199) without multimorbidity reported pain
interfering with work, compared to 62.4% (128/205)
who had multimorbidity (OR = 3.3 95%CI: 2.0, 5.6). In
those with another form of musculoskeletal condition
(other than soft-tissue disorder, n = 4151), those with
multimorbidity also reported higher rates of pain
interfering with work (45.9%, 747/1627) compared to
those without multimorbidity (27.1%, 684/2524, OR =
1.8 95%CI: 1.4, 2.3), but this association was weaker
than that seen in those with a soft tissue disorders
(interaction p-value = 0.03).
Musculoskeletal condition, multimorbidity and
musculoskeletal related healthcare utilisation and
medicines use
After adjusting for SES, education, smoking and medium to
high risk alcohol consumption (Table 5) among working-
age adults with specific musculoskeletal conditions there
were minimal differences in associations between the pres-
ence and absence of multimorbidity in the measures of
musculoskeletal healthcare utilisation (Table 5).
The interaction analyses identified two exceptions.
The association between multimorbidity and pain medi-
cine use was weaker among those with “other arthritis”
compared to those with the remaining musculoskeletal
conditions (Table 5). Specifically, of working-age adults
with “other arthritis” (n = 1022), in the absence of multi-
morbidity, 4.1% (n = 24/586) reported pain medicines
use, compared to 8.0% (n = 35/436) when multimorbidity
was present. In those with a musculoskeletal condition
other than “other arthritis” (n = 3533), those with multi-
morbidity also reported higher rates of pain medicines
use (8.7%, n = 122/1396) compared to those without
multimorbidity (2.7%, n = 57/2137, but this association
(OR = 4.0 95%CI: 2.4, 6.9) was stronger (interaction
p-value = 0.014) than that seen in those with “other
arthritis” (OR = 2.1, 95%CI: 1.2, 3.8).
The association between multimorbidity and muscu-
loskeletal medicines use was stronger in respondents
with gout than those with the other musculoskeletal
conditions (Table 5). Specifically, of working-age adults
with gout (n = 589), 15.9% (n = 55/345) without multimor-
bidity reported musculoskeletal medicines use, compared
to 29.1% (n = 71/244) who had multimorbidity (OR = 2.4
95%CI: 1.2, 5.1). In those with another form of musculo-
skeletal condition (other than gout, n = 3966), those with
multimorbidity reported higher rates of musculoskeletal
medicines use (30.3%, n = 481/1588) compared to those
without multimorbidity (24.1%, n = 572/2378, OR = 1.3,
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95%CI: 1.0, 1.6), but this association was weaker than that
seen in those with gout (interaction p-value = 0.040). It
should be noted that this apparent stronger association
in respondents with gout is due to musculoskeletal
medicines use being less common (15.9%) in respondents
with gout, than for the remainder of musculoskeletal
conditions (24.1%) in the absence of multimorbidity.
Yet, in the presence of multimorbidity there was lit-
tle difference in the prevalence of musculoskeletal
medicines use by respondents with gout (29.1%) and
all other musculoskeletal conditions (30.3%). This indi-
cates that, in the absence of multimorbidity, respondents
with gout are less likely to use musculoskeletal medicines
than those with another form of musculoskeletal
condition.
Musculoskeletal condition, multimorbidity and general
healthcare utilisation
Among the combined musculoskeletal working-age popula-
tion, multimorbidity was associated with consulting a
Table 5 Associationsa and interactionsb between multimorbidity and musculoskeletal-related healthcare or medicines use among
working-age adults with specific musculoskeletal conditions
Sample
(n = 4555)
Visit arthritis or
osteoporosis
specialist (n = 103)
OR (95%CI)
Interaction
p-valueb
Visit GP for arthritis
or osteoporosis
(n = 206)
OR (95%CI)
Interaction
p-value
Pain medicines use
(n = 238)
OR (95%CI)
Interaction
p-value
MSK
medicines use
(n = 1179)
OR (95%CI)
Interaction
p-value
Any MSK (4555) 1.4 (0.7, 2.8) - 1.4 (1.0, 2.2) - 3.2 (2.1, 5.1) - 1.3 (1.1, 1.7) -
Osteoarthritis (993) 1.7 (0.5, 5.6) 0.68 2.1 (1.0, 4.1) 0.30 3.5 (1.7, 7.5) 0.91 1.3 (1.0, 1.9) 0.98
Inflammatory
arthritis (317)
0.8 (0.1, 4.9) 0.59 0.7 (0.1, 6.1) 0.43 2.9 (0.7, 12.2) 0.51 0.8 (0.3, 1.9) 0.08
Other arthritis (1022) 1.3 (0.5, 3.2) 0.79 2.3 (0.9, 6.1) 0.21 2.1 (1.2, 3.8) <0.05 1.0 (0.7, 1.6) 0.11
Gout (589) NE NE 20.8 (2.8, 157.9) 0.84 10.0 (1.4, 71.8) 0.40 2.4 (1.2, 5.1) <0.05
Back pain (2493) 3.0 (0.7 13.9) 0.23 2.6 (1.0, 7.2) 0.14 3.9 (2.0, 7.8) 0.40 1.7 (1.2, 2.3) 0.06
Soft tissue
disorder (404)
1.4 (0.0, 164.0) 0.93 2.6 (0.7, 10.2) 0.34 4.0 (1.0, 16.0) 0.96 2.2 (1.2, 4.0) 0.17
Osteoporosis (292) 1.0 (0.4 2.4) 0.92 1.0 (0.4, 2.1) 0.94 3.4 (0.9, 13.8) 0.68 1.6 (0.8, 3.4). 0.91
legend: aEach row header indicates the specific MSK in which the strata-specific association between multimorbidity and each burden measure has been
estimated. For each row, the reference group is those with the specific MSK but not multimorbidity. Associations (odds ratios) are adjusted for age, gender, SES,
education, smoking and medium to high risk alcohol consumption. All musculoskeletal-related healthcare and medicines use measures relate to the 2 weeks prior
to the interview. NE: not estimable due to small cell counts. bEach interaction p-value indicates whether the association between multimorbidity and the health
measure differs between the specific MSK group and the remaining MSK population. Significant (p < 0.05) interactions are bolded and further details are presented
textually in results section. GP: general practitioner
Table 4 Associationsa and interactionsb between multimorbidity and self-reported health measures among working-age adults with
specific musculoskeletal conditions
Sample (n = 4555) Fair to poor health
status (n = 1073)
OR (95%CI)
Interaction
p-valueb
High distress
(n = 865)
OR (95%CI)
Interaction
p-value
Pain interference
with activities
(n = 1633)
OR (95%CI)
Interaction
p-value
Moderate to
severe pain
(n = 2086)
OR (95%CI)
Interaction
p-value
Any MSK (4555) 3.5 (2.7, 4.4) - 6.0 (4.8, 7.3) - 2.0 (1.6, 2.4) - 1.9 (1.5, 2.3) -
Osteoarthritis (993) 3.9 (2.2, 7.0) 0.77 6.1 (3.6, 10.2) 0.53 1.8 (1.2, 2.8) 0.56 2.1 (1.3, 3.3) 0.94
Inflammatory
arthritis (317)
3.9 (1.4, 10.4) 0.27 5.4 (2.1, 14.0) 0.52 2.9 (1.3, 6.8) 0.43 2.3 (1.0, 5.3) 0.55
Other arthritis (1022) 3.4 (1.9, 5.8) 0.76 4.8 (2.8, 8.2) 0.16 1.9 (1.3, 3.0) 0.73 2.1 (1.4, 3.2) 0.82
Gout (589) 3.8 (1.8, 7.9) 0.41 7.2 (2.9, 17.9) 0.55 2.6 (1.4, 4.7) 0.54 1.7 (1.0, 2.9) 0.83
Back pain (2493) 3.8 (2.8, 5.2) 0.34 8.0 (6.0, 10.8) <0.01 2.1 (1.6, 2.7) 0.13 2.0 (1.5, 2.7) 0.18
Soft tissue
disorder (404)
4.0 (1.8, 9.0) 0.86 5.0 (2.0, 12.8) 0.36 3.3 (2.0, 5.6) <0.05 2.1 (1.1, 3.7) 0.99
Osteoporosis (292) 5.1 (1.9, 14.0) 0.86 5.8 (2.1, 16.1) 0.37 3.4 (1.4, 8.3) 0.24 3.6 (1.5, 8.7) 0.17
legend: aEach row header indicates the specific MSK in which the strata-specific association between multimorbidity and each burden measure has been
estimated. For each row, the reference group is those with the specific MSK but without multimorbidity. Associations (odds ratios) are adjusted for age, gender,
SES, education, smoking and medium to high risk alcohol consumption. All ratings of self-reported health burden relate to the 4 weeks prior to the interview.
bEach interaction p-value indicates whether the association between multimorbidity and the health measure differs between the specific MSK group and the
remaining MSK population. Significant (p < 0.05) interactions are bolded and further details are presented textually in results section
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specialist for conditions other than arthritis/osteoporosis;
and chemist(s) for advice; but not visiting physiothera-
pist(s) or chiropractor(s); and was protective against not
consulting a health professional during the past year
(Table 6). Furthermore, there were minimal differences in
the associations between multimorbidity and these general
healthcare utilisation burden measures across working-
age adults with the specific musculoskeletal conditions
(Table 6).
Interaction analyses identified there was a greater
association between multimorbidity and consulting a
chemist for advice only (interaction p-value = 0.015)
among those with inflammatory arthritis compared to
those with the remaining musculoskeletal conditions
(Table 6). Specifically, of working-age adults with inflam-
matory arthritis (n = 317), 14.3% without multimorbidity
(n = 21/147) reported consulting a chemist for advice
only, compared to 30.2% (n = 52/170) who had multi-
morbidity (OR = 4.9, 95%CI: 2.1, 11.4). In those with
another form of musculoskeletal condition (other than
inflammatory arthritis, n = 4238), those with multimor-
bidity reported higher rates of consulting a chemist for
advice only (21.6%, n = 359/1662) than those without
multimorbidity (13.5%, n = 347/2576, OR = 1.8, 95%CI:
1.5, 2.3), but this association was weaker than that seen
in those with inflammatory arthritis (interaction p-value
= 0.015). Additionally, multimorbidity was associated
with an increased likelihood of consulting a specialist for
a non-arthritis condition across the majority of the
specific musculoskeletal conditions, but not in those
with inflammatory arthritis. Specifically, of working-age
adults with inflammatory arthritis (n = 317), 46.9%
(n = 69/147) without multimorbidity reported consulting
a specialist for a non-arthritis condition, compared to
56.5% (n = 96/170) who had multimorbidity (OR = 0.9,
95%CI: 0.4, 2.1). In contrast, in those with another form of
musculoskeletal condition (other than inflammatory arth-
ritis, n = 4238), those with multimorbidity reported higher
rates of consulting a specialist for a non-arthritis condition
(43.9%, n = 730/1662) than those without multimorbidity
(24.0%, n = 618/2576, OR = 2.5, 95%CI: 2.1, 3.0), and this
association was stronger than that seen in those with in-
flammatory arthritis (interaction p-value = 0.004).
Discussion
In this population representative sample of community
dwelling adults aged 18 to 64 years, for each of the
specified musculoskeletal conditions there were minimal
differences in associations between multimorbidity and
self-rated measures of health burden or certain types of
healthcare utilisation. Specifically, associations between
multimorbidity and additional self-rated health, distress
and pain burden measures were higher and relatively
consistent across each of these specific musculoskeletal
conditions. Also, for the majority of these specified
musculoskeletal conditions, multimorbidity was strongly
associated with the health utilisation measures of
visiting general practitioner (GP) for arthritis or
osteoporosis and visiting specialists for conditions
other than arthritis or osteoporosis, pain and musculo-
skeletal medicine use, and consulting chemist for advice,
but not visiting specialists for arthritis or osteoporosis, vis-
iting physiotherapist(s) or chiropractor(s).
Despite these overall findings, interaction analyses did
identify limited instances where associations between
multimorbidity and some burden measures were more
pronounced for some specific musculoskeletal condi-
tions. In particular, there was a much stronger associ-
ation between multimorbidity and consulting a chemist
(for advice only) among those with inflammatory arth-
ritis compared to those with the remaining musculoskel-
etal conditions. This may be due to inflammatory
conditions, such as rheumatoid arthritis, requiring com-
plex medication management that, in the presence of
additional conditions and their respective medications,
raises the possibility of drug interactions and increases
the need for advice seeking. Furthermore, the relation-
ship between multimorbidity and the measure “high dis-
tress” was significantly greater in those with back pain
compared to the remainder of the musculoskeletal popu-
lation. This was not simply due to pain or mental health
issues being more common, as multimorbidity was not
more strongly related to ratings of moderate to severe
pain in those with back pain when compared to those
with another form of musculoskeletal condition. Fur-
thermore, mental health conditions were not particularly
more common in those with back pain, when compared
to other forms of musculoskeletal conditions. These ob-
servations may indicate that a more holistic, person
centred, treatment approach for additional conditions
alongside back pain may be needed. Similarly, the ob-
served association for multimorbidity on “pain interfer-
ing with work” was significantly stronger for those with
soft-tissue disorders than the rest of the musculoskeletal
population, suggesting that additional support strat-
egies for improving return to work could be indicated
for individuals with soft tissue conditions alongside
other conditions.
Conversely, for some specific musculoskeletal condi-
tions, the associations between multimorbidity and some
burden measures were significantly weaker. For example,
associations between multimorbidity and pain medicines
use were weaker for those with “other arthritis” than the
remaining musculoskeletal groups. However, both the
“other arthritis” group and those with the remaining
musculoskeletal conditions had equivalent proportions
reporting pain medicines use in the presence of multi-
morbidity; whereas, in the absence of multimorbidity the
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prevalence of pain medicines use was much higher for
those with “other arthritis” than for those with the
remaining musculoskeletal conditions, thus creating a
weaker association. Again, in the presence of multi-
morbidity the proportion reporting musculoskeletal
medicines use among those with gout and the remaining
musculoskeletal groups were equivalent, but in the ab-
sence of multimorbidity, musculoskeletal medicines use
was lower in those with gout (than the remaining mus-
culoskeletal group), suggesting those with uncomplicated
gout are less likely to use these medicines. Finally, the
association between multimorbidity and consulting a
specialist for a non-arthritis condition (i.e. “other spe-
cialists”) in those with “inflammatory arthritis” was sig-
nificantly weaker, even though the proportion of people
visiting “other specialists” in the presence of multimor-
bidity was higher in this group than the remaining mus-
culoskeletal population. The association was weaker
because, in the absence of multimorbidity, the propor-
tion visiting “other specialists” was much higher in those
with inflammatory arthritis than the remaining musculo-
skeletal population. A possible interpretation of the
higher rate of visiting “other specialists” in the absence
of multimorbidity is that the conditions included in pol-
icy definition do not adequately capture the experience
of “other” conditions for working-age adults with inflam-
matory arthritis.
The associations with multimorbidity observed here
are similar to those in previous studies with comparable
objectives despite a focus on a limited spectrum of arth-
ritis conditions [29], and rheumatic conditions [30] or
both [39]. In the study by Mavaddat et al., who sampled
from GP settings [29], the association between multi-
morbidity (defined as arthritis plus one of cancer, stroke,
heart attack, diabetes, arthritis or respiratory illnesses)
and self-rated fair to poor health was OR 1.5 (95% CI:
1.3, 1.7); and arthritis in the presence of two additional
conditions was associated with a greater increase likeli-
hood of self-rated fair to poor health 3.0 (95% CI: 2.1-
4.1). In Loza et al.’s study, when multimorbidity included
a rheumatic condition, subjective health-related quality
of life and daily functioning was worse than multimor-
bidity that did not include a rheumatic condition [30].
Similar to our findings, co-morbidity negatively im-
pacted physical and mental health equally according to
those with either rheumatoid arthritis or osteoarthritis
[39]. Collectively, these results support the finding of
additional burden caused by multimorbidity on individ-
uals with musculoskeletal conditions. Our finding that
the proportions of the working-age adults with specific
additional conditions did not vary greatly across the
specific musculoskeletal conditions supports previous re-
search that similarly found that the proportions of the
arthritis sample with particular comorbidities did not vary
substantially with the type of arthritis (osteoarthritis,
rheumatoid arthritis, rheumatism, other arthritis) [47].
Within this study, we elected to define multimorbidity
as the presence of one or more of the Australian Na-
tional Health Priority Area conditions [45] in addition to
a musculoskeletal condition (listed above). We have termed
this the “policy definition” of multimorbidity [40, 41]. As
there isn’t a gold standard for operationalising multimor-
bidity based on condition counts, we have previously exam-
ined three potential definitions. While these definitions
resulted in highly variable estimates of prevalence of multi-
morbidity [40], all definitions examined were similar in
terms of associations with burden [41]. However, the policy
definition was more strongly associated with distress [41].
We elected to use the policy definition of multimorbidity
within this study, as it produced an intermediate estimate
of prevalence, and generated similar strengths of associa-
tions with subjective health outcomes among the musculo-
skeletal population as the other assessed definitions. If we
had chosen a different definition, the specific association
estimates would have been different, but it is unlikely that
this would have materially altered the study findings
due to the inherent nature of dichotomous cut-
points flattening associations [41]. The associations
reported for the overall musculoskeletal group are
slightly different than in a previous paper [41], as we
adjusted here for additional factors beyond age,
gender as potential confounders (household income
quintiles as a marker of socioeconomic status (SES),
education, smoking status (current, past, never), and
moderate to high risky alcohol consumption). Adjusting
for the additional factors generally resulted in reducing
the strength of associations (by no more than 15%),
but did not change the direction or interpretation in
any instance.
This study has a number of strengths and limitations.
Although we observe interactions, given a large number
of exploratory analyses were performed, it is possible
that some of the observed interactions are spurious.
Given the multiple testing and the age of the dataset,
these analyses should be replicated in future research.
The strengths of this study are that it is nationally repre-
sentative, with a large sample size, and a comprehensive
range of subjective measures of health status, distress,
pain, healthcare utilisation, and medicines use. This
allowed a comprehensive approach to examining the
additional health burden of multimorbidity for working-
age adults with a range of musculoskeletal conditions.
While the total sample size was quite large, the “other
musculoskeletal” group was small in this sample, result-
ing in imprecise estimates of associations for the associa-
tions between multimorbidity and the health status and
utilisation measures. For this reason, we elected not to
present these results. A larger population sample, or a
Lowe et al. BMC Musculoskeletal Disorders  (2017) 18:135 Page 11 of 14
selected clinical sample, may be required to address this
issue in this sub-population. Both the exposures (report
of doctor diagnosis of conditions) and outcomes (health
and healthcare utilisation measures) were based on
participant recall. Reported conditions were therefore
salient to the respondents, but may potentially be
subject to recall error. Recall error may overestimate as-
sociations because identifying symptom-based condi-
tions may also mean those with poorer health may recall
more symptoms. However, there is no clear reason to
believe that this recall bias should be different between
people with specific musculoskeletal conditions or for
those with or without multimorbidity, which is the
focus of this study. Additionally, a limitation of using
population-based survey data is that self-report of
arthritis may not be discriminating enough to allow
for exploration of within sub-group analyses [47]. The
cross-sectional design of this study does not allow for
examination of temporality of associations. However,
given poor quality of life does increase risk of de-
pression and chronic pain, longitudinal studies are
required to examine the temporality of poor health status
and multimorbidity or musculoskeletal conditions.
This study extends previous research examining asso-
ciations between multimorbidity and health status and
utilisation measures to determine whether there is a
particular musculoskeletal sub-population for whom the
additional burden of multimorbidity is most pronounced.
We found that the additional health burden of multimor-
bidity is an issue for all of these specific musculoskeletal
conditions and this highlights the need for proactive
healthcare management, such as contemporary models of
care, whereby the principles of chronic care are integrated
within an interdisciplinary team that supports and in-
volves the patient in their care planning [48]. A range of
strategies to deal with multimorbidity in health services
have been evaluated [49, 50]. However, intervention trials
in these reviews are focused on multimorbidity (or com-
mon combinations of comorbidities) that do not include a
musculoskeletal condition and populations rarely include
those aged less than 65 years [49, 50]. Nonetheless, some
strategies might also be relevant to all adults with multi-
morbidity as a way of improving care continuity or opti-
mising care or treatments by tailoring them to meet a
person's needs [49]. In these reviews, a limited number of
trials are of some relevance to multimorbidity/comorbid-
ity that includes a musculoskeletal condition with only a
subset of the population under the age of 65 years, these
interventions show some limited, small or mixed benefits
across a range of health outcomes [51–55]. It is therefore
perhaps unsurprising that adults and younger people with
musculoskeletal conditions [56, 57] identify a number of
unmet healthcare service and information needs. These
unmet needs can help inform improvements to existing
models of care and furthermore emphasise the need
to involve consumers in implementation of models of
care. Promising strategies for involving consumers
when designing and delivering models of care, include
consumer involvement in: developing guidelines, identify-
ing barriers to implementation and tailoring implementa-
tion strategies [58]. By focusing on working-age adults, we
extend previous research, which has focused primarily on
older people. Our findings emphasise that multimorbidity
is associated with additional impact among working-age
people. We were interested in the subjective burden of
multimorbidity compared to the subjective burden of
musculoskeletal conditions. So, while the multimorbid
musculoskeletal population may also be considered comor-
bid we use the term multimorbidity as we are not technic-
ally applying an index condition, rather, the sample is
the musculoskeletal population, and the exposure is
the presence of multimorbidity.
Conclusions
Among working-age adults with any musculoskeletal
conditions examined here, multimorbidity was associ-
ated with similar increases in all self-reported health and
some healthcare utilisation burden measures. The impli-
cation of these findings is that there is little rationale,
based on health status or health utilisation burden, for
directing interventions to improve outcomes of individ-
uals with multimorbidity to only people with a specific
musculoskeletal condition. The additional burden of
multimorbidity among the working-age population with
a range of musculoskeletal conditions highlights the
need to better understand and identify strategies that
acknowledge and address the issues of concomitant
conditions. However, an approach targeted to those with
only specific musculoskeletal conditions at the exclusion
of all others could arguably worsen burden associated
with multimorbidity or be otherwise inequitable.
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